A randomised, double-blind, placebo-controlled trial of Vitamin D supplementation in the management of symptomatic knee osteoarthritis (the VIDEO study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN94818153

Enrollment

800

Registered

2005-05-03

Start date

2004-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis Musculoskeletal Diseases Knee osteoarthritis

Interventions

Participants will be randomised to receive oral vitamin D (as cholecalciferol) 800 IU/day (20 µg/day) or matching placebo tablets.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Participants aged over 50 2. Male or female 3. Ambulatory (not wheelchair bound) 4. Able and willing to attend or comply with treatment and follow-up 5. Radiological evidence of early disease at medial tibio-femoral knee compartment (modified Kellgren & Lawrence [k&l] score 2/3, joint space width [JSW] >1 mm) 6. Pain in knee for most days of previous month 7. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Secondary osteoarthritis (OA), septic arthritis, gout, Wilson's disease, Paget's disease, pseudo gout 2. History of inflammatory arthritis 3. Knee stiffness >30 minutes duration 4. Current user of cod liver oil or vitamin D supplementation 5. Current use of glucosamine or chondroitin for less than 3 months 6. History of hyperparathyroidism or osteomalacia 7. Current use of anti-epileptic medication 8. Current use of bisphosphonates or use within 2 years 9. History of hypercalcaemia or hypercalciuria 10. History of hyperthyroidism, sarcoidosis 11. History of renal stones 12. Previous intra-articular injection: steroid within 3 months, hyalgan within 6 months 13. Previous knee surgery or arthroscopy within 6 months 14. History of osteoporotic fracture 15. History of cancer within last 5 years, excluding skin cancer 16. Serious psychiatric disorders including dementia 17. Inability to understand the procedures 18. Inability to attend or comply with treatment or follow-up scheduling 19. Pregnancy

Design outcomes

Primary

Measure	Time frame
Radiological progression of knee OA in medial joint compartment at 36 months	—

Secondary

Measure	Time frame
1. Radiological progression of knee OA in other joint compartments 2. Reduction in pain and functional disability 3. Improvement in quality of life	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026